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Abstract Gold nanoparticles functionalized with thiolated ol-
igonucleotides (Au-nanoprobes) have been used in a range of
applications for the detection of bioanalytes of interest, from
ions to proteins and DNA targets. These detection strategies
are based on the unique optical properties of gold nanoparti-
cles, in particular, the intense color that is subject to modula-
tion by modification of the medium dieletric. Au-nanoprobes
have been applied for the detection and characterization of
specific DNA sequences of interest, namely pathogens and
disease biomarkers. Nevertheless, despite its relevance, only
a few reports exist on the detection of RNA targets.
Among these strategies, the colorimetric detection of DNA
has been proven to work for several different targets in con-
trolled samples but demonstration in real clinical bioanalysis
has been elusive. Here, we used a colorimetric method based
on Au-nanoprobes for the direct detection of the e14a2 BCR-
ABL fusion transcript in myeloid leukemia patient samples
without the need for retro-transcription. Au-nanoprobes di-
rectly assessed total RNA from 38 clinical samples, and
results were validated against reverse transcription-nested po-
lymerase chain reaction (RT-nested PCR) and reverse
transcription-quantitative polymerase chain reaction (RT-
qPCR). The colorimetric Au-nanoprobe assay is a simple yet
reliable strategy to scrutinize myeloid leukemia patients at
diagnosis and evaluate progression, with obvious advantages
in terms of time and cost, particularly in low- to medium-
income countries where molecular screening is not routinely
feasible.
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Introduction
Gold nanoparticles functionalized with thiolated oligonucleo-
tides (Au-nanoprobes) due to their unique optical proprieties
have been widely used for nucleic acid detection with high
sensibility and sensitivity at much lower costs when compared
with conventional molecular methods. Disperse Au-
nanoprobe solutions show a characteristic surface plasmon
resonance (SPR) band at around 525 nm (red color), which
is red-shifted upon salt-induced aggregation (blue color); hy-
bridization to a complementary nucleic acid target sequence
prevents aggregation and the solution remains red [1]. This
non-cross-linking colorimetric detection method has been ef-
ficiently applied to the detection of pathogens and other DNA
sequences of interest, where hybridization to a specific com-
plementary target leads to Au-nanoprobe stabilization and re-
sistance to salt-induced aggregation [2, 3].
Chronic myeloid leukemia (CML) is a clonal bone marrow
stem cell disease with an annual incidence of 1–2 new cases
per 100,000 adults and accounting for approximately 15 % of
leukemia cases. CML is one of the rarest forms of leukemia,
which is expected to become the most prevalent hematologic
malignancy in the world by 2020 [4–6]. Management of CML
therapy with tyrosine kinase inhibitors (TKIs) has been suc-
cessfully achieved [7–10]. The Philadelphia chromosome
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(Ph), a reciprocal translocation of the long arms of
chromosomes 9 and 22, t(9;22), is found in more than
90 % patients with CML, 15–25 % of patients with
acute lymphoblastic leukemia (ALL), and 1 % of newly
diagnosed adults with acute myeloid leukemia (AML)
[11–13]. This translocation transposes the ABL1 onco-
gene from chromosome 9q34 to the BCR gene on chro-
mosome 22q11 (Fig. 1) [14–16].
This reciprocal translocation during hematopoiesis com-
bined with alternative splicing events may originate at least
eight different reported BCR-ABL1 transcripts, all encoding
proteins with high tyrosine kinase activity. The vast majority
of patients with CML (∼95 %) express either e13a2 or e14a2
mRNAs that result from a rearrangement of the major
breakpoint cluster regions (M-BCR) generating 210-
kDa fusion proteins (Fig. 1c). Several studies suggest
that not only qualitative differences in the type of
BCR-ABL1 proteins expressed but also quantitative var-
iations in their total level within the cells may have an
important role in determining CML phenotype [17–20].
The fused BCR-ABL1 gene and its gene products pro-
vide specific markers for diagnosis and disease monitor-
ing. Currently, CML diagnosis is primarily based on
clinical symptoms, complete blood count, and bone
marrow biopsy. Cytogenetic analysis, such as karyotype
and fluorescence in situ hybridization (FISH), may be
carried out to check the presence of the Ph chromo-
some, and molecular tests, e.g., reverse transcription-
polymerase chain reaction (RT-PCR) and reverse
transcription-quantitative polymerase chain reaction
(RT-qPCR), are used for assessing type and levels of
fusion transcript on RNA from bone marrow or periph-
eral blood specimen [21, 22]. Monitoring CML by RT-
qPCR and RT-nested PCR depends on local facilities
and on the degree of molecular standardization of the
local laboratory [23–25].
Based on their size-dependent surface plasmon resonance
(SPR) absorption and the high surface-to-volume ratio
allowing for surface functionalization with a variety of mole-
cules, gold nanoparticles (AuNPs) are frequently used as
probes in biological detections [1, 2]. Baptista and colleagues
developed a proof-of-concept colorimetric Au-nanoprobe
method for direct detection and quantification of a BCR-
ABL1 e14a2 fusion suitable for identification of BCR-ABL
targets in lab-controlled conditions [3]. Contrary to the
existing molecular tools for the diagnostics of CML, the Au-
nanoprobe methodology requires neither retrotranscription of
the sample RNA into cDNA nor its amplification in a nested-
PCR format with extreme complexity. Despite several reports
on the use of BCR-ABL target as proof-of-concept for
nanotechnology-based detection, the use of nanoparticles for
CML diagnostics in clinical samples has never been per-
formed before.
Here, we were able to directly screen RNA extracted from
blood or bone marrow samples from patients admitted to the
clinics for CML or AML via the Au-nanoprobe assay and
validated results against the gold standard, RT-nested PCR
and qPCR, without loss of information.
Fig. 1 Genetics of CML. a Chromosomes reciprocal translocation that
originates the BCR-ABL1 oncogene during hematopoiesis. b Structure of
BCR and ABL1 genes. c Structure of the two most common BCR-ABL1
fusion transcripts (e14a2 and e13a2) and a rare one (e1a2). e14a2 and
e13a2 isoforms encode 210 kDa fusion proteins, and the e1a2 isoform
encodes a 190-kDa protein. d Au-nanoprobe designed to target e14a2
mRNA
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Patients and methods
Patient samples
All CML patients were confirmed to harbor the t(9;22)
by FISH. Levels of BCR-ABL1 were assessed using RT-
qPCR, according to the 2015 European LeukemiaNet
(ELN) guidelines [26]. Treatment with TKIs was initiat-
ed immediately and clinical, hematological, and molec-
ular remission was evaluated. All 16 AML bone marrow
samples were collected at diagnosis, presenting a normal
karyotype and negative t(9;22) FISH analysis (Table 1).
Bone marrow and peripheral blood patient samples were
collected in RNAlater® (Thermo Fisher Scientific,
Carlsbad, CA, USA) for maximum RNA stabilization
and used directly for RNA extraction without any cul-
ture expansion and/or any cell culture method.
Au-nanoprobe synthesis
The probe sequence and the complementary target de-
rive from the BCR-ABL1 e14a2 (also known as b3a2)
chimeric protein mRNA. This target was selected be-
cause it represents the most frequent breakpoint in
CML, accounting for 55 % of cases [27, 28]. Probe
selectivity was assessed against two other BCR-ABL1
breakpoint regions: e13a2 and e1a2. Control oligonucle-
otide target sequences included BCR, ABL1, and an un-
related target—see Electronic Supplementary Material
Table S1.
Au-nanoprobe design and synthesis were performed as pre-
viously described [3]. In brief, 14-nm gold nanoparticles were
prepared by the citrate reduction method and functionalized
with the respective thiolated oligonucleotide in an aqueous
solution of AuNPs at a 1:150 (AuNP:oligonucleotide) ratio
for 16 h. After centrifugation (20 min at 14,500g), the oily
precipitate was washed with 10 mM phosphate buffer
(pH 8.0), 0.1 M NaCl, centrifuged, and resuspended in the
same buffer. The resulting Au-nanoprobes were stored in the
dark at 4 °C.
Characterization of AuNPs and Au-nanoprobes was
performed by transmission electron microscopy and dy-
namic light scattering (see Electronic Supplementary
Material Table S2).
Cell culture
Immortalized cell lines derived from CML patients in
blast crisis, K562 (BCR-ABL1 e14a2 fusion transcript
positive cell line) and BV173 (BCR-ABL1 e13a2 fusion
transcript positive cell line; e14a2 negative) [28] were
cultured, respectively, in DMEM and RPMI with 10 %
FBS, a t 37 °C wi th 5 % CO2. Human acute
promyelocytic leukemia cell line (HL60), negative for
BCR-ABL1, was cultured in RPMI with 10 % FBS, at
37 °C with 5 % CO2. These cell lines were used as
positive and negative controls for the presence and ab-
sence of BCR-ABL1 transcript, respectively.
Total RNA isolation
Total RNAwas extracted from (1) K562, BV173, and HL60
cell pellets and from (2) bone marrow and peripheral blood
patient samples previously stored in RNAlater® (Thermo
Fisher Scientific, Carlsbad, CA, USA). Patients’ bone marrow
or white blood cells were used directly for RNA extraction
and not expanded by any cell culture method. RNA extraction
was performed by the guanidine thiocyanate procedure (SV
Total RNA Isolation System, Promega, Madison, WI, USA).
Cell pellets were lysed in a solution containing 4 M guanidine
thiocyanate, 0.1 M Tris-HCl pH 7.5, and 1 % β-
mercaptoethanol and were subsequently centrifuged at 13,
000×g for 10 min to clear the lysate of precipitated proteins
and cellular debris. Nucleic acids were selectively precipitated
with ethanol; bound to the silica surface of glass fibers; and
washed with 60 mM potassium acetate, 10 mM Tris-HCl
pH 7.5, and 60% (v/v) ethanol. On-column DNase I treatment
lasted for 15 min at room temperature to remove genomic
DNA. After several washing steps, RNAwas resuspended in
DEPC-treated water and stored at −80 °C until use. RNA
concentration and purity were determined by UV
spectrophotometry.
RT and PCR amplification
Total RNA extracted from samples was reverse tran-
scribed using the NZY M-MuLV First-Strand cDNA
Synthesis kit (Nzytech, Lisbon, Portugal) followed by
nested-PCR amplification (see primer sequences under
Electronic Supplementary Material Table S1). Outer
PCR was performed under the following conditions: ini-
tial denaturation at 95 °C for 5 min; 30 cycles of 94 °C
for 30 s, 55 °C for 30 s, 72 °C for 1 min; and a final
extension step at 72 °C for 10 min. Inner PCR included
the following conditions: initial denaturation at 95 °C
for 5 min; 30 cycles of 94 °C for 15 s, 55 °C for
30 s, 72 °C for 1 min; and a final extension step at
72 °C for 10 min.
Colorimetric detection with Au-nanoprobes
The Au-nanoprobe assay was performed in a total volume of
30 μL containing the Au-nanoprobe at a final concentration of
2.5 nM and the appropriate targets at a final concentration of
0.33 μM in 10 mM phosphate buffer (pH 8.0). A blank reac-
tion was made in exactly the same conditions but replacing
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target or total RNA by an equivalent volume of 10 mM phos-
phate buffer (pH 8.0). Following 5 min of denaturation at
95 °C, the mixtures were cooled down to 25 °C and 80 mM
MgCl2 added for color revelation. Absorption spectra were
run in a Tecan Infinite® M200 microplate reader
(Männedorf, Switzerland). Aggregation profiles were
in te rpre ted based on the areas under the curve
(rAbs=AUC500–530 nm/AUC570–600 nm) using the trapezoidal
rule. Au-nanoprobe aggregation is portrayed by the natural
logarithm of rAbs: a value of 0 for the ln (rAbs) is considered
Table 1 Performance of Au-





AML at diagnostics 1 BM n/a No amp −
2 BM n/a No amp −
3 BM n/a No amp −
4 BM n/a No amp −
5 BM n/a No amp −
6 BM n/a No amp −
7 BM n/a No amp −
8 BM n/a No amp −
9 BM n/a No amp −
10 BM n/a No amp −
11 BM n/a No amp −
12 BM n/a No amp −
13 BM n/a No amp −
14 BM n/a No amp −
15 BM n/a No amp −
16 BM n/a e14a2 +
CML at diagnostics 17 BM n/a e14a2 +
18 BM n/a e13a2 −
19 BM n/a e14a2 +
20 BM n/a e14a2 +
21 BM n/a e13a2 −
22 BM n/a e14a2 +
23 BM 98 % e13a2 −
24 BM 87 % e14a2 +
25 BM 98 % e14a2 +
26 BM 97 % e14a2 +
27 BM 95 % e13a2 −
28 BM 99 % e13a2 −
29 BM 77 % e14a2 +
30 BM 95 % e14a2 +
31 BM 98 % e14a2 +
32 PB 90 % e13a2 −
CML at follow-up 33 PB 0.017 % No amp −
34 PB 0.34 % e14a2 +
35 PB 0.00031 % No amp −
36 PB 0.11 % e13a2 −
37 PB 1 % No amp −
38 PB 3.4 % e13a2 −
IS international scale, n/a not available, No amp no amplification, BM bone marrow, PB peripheral blood
a FISH analysis for diagnostic samples (1–32) and RT-qPCR analysis for follow-up samples (33–38)
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as the threshold for distinction between non-aggregated [ln
(rAbs)≥0] and aggregated [ln (rAbs)<0] Au-nanoprobe, cor-
responding to a positive and a negative sample, respectively.
The accuracy of the Au-nanoprobe assay was assessed calcu-
lating positive and negative predictive values (PPVand NPV,
respectively), by comparison to the gold-standard methodol-
ogy, RT-PCR. These proportions determine the positive re-
sults that are true-positive hits [PPV=number of positives (gold
standard)/number of positives (Au-nanoprobe)] and the negative re-
sults that are true negative hits [NPV=number of negatives
(gold standard)/number of negatives (Au-nanoprobe)].
Statistical analysis
A one-way analysis of variance (ANOVA) and a post hoc
Tukey’s test were carried and mean differences (P value
<0.001) between groups determined with a confidence inter-
val (CI) of 99 %.
Results
Au-nanoprobe calibration
Molecular diagnostics of CML usually involves the detection
of the BCR-ABL1 e14a2 fusion transcript. First, we calibrated
the Au-nanoprobe to selectively identify this fusion transcript
using synthetic oligonucleotides as targets for hybridization.
Figure 2 shows that the Au-nanoprobe was able to discrimi-
nate between the fully complementary target and two other
BCR-ABL1 fusion transcripts that share the same ABL1 region
as the e14a2 transcript (e13a2 and e1a2) at 100 fmol/μl of
ssDNA oligo. One can observe the selectivity of the Au-
nanoprobe towards the e14a2 transcript, as the values for
BCR, ABL1, and non-complementary targets are below the
defined threshold.
Total RNA extracted from K562 (harboring the target
e14a2 fusion transcript), BV173 (harboring the e13a2
fusion transcript), and HL60 (promyelocytic leukemia
cell line without fusion transcript) was used to calibrate
for complex sample mixtures. The Au-nanoprobe was
able to recognize the e14a2 sequence present in K562
cells, with identical specificity as that attained for syn-
thetic oligonucleotides (Fig. 3).
RNA extracted from HL60 and BV173 cell lines was
scored as negative despite the presence of partially com-
plementary targets: BCR, ABL1, and e13a2 mRNA
(Fig. 3b). The obtained value is clearly below the
established threshold indicating that the system is capa-
ble to selectively detect only the correct target sequence
even in presence of similar sequences with more than
50 % homology to the target. The colorimetric data is
in clear agreement with that of the gold standard, RT-
PCR [26, 27]. The LOD=15 ng/μl is ideal and critical
for optimal performance and sequence discrimination di-
rectly from RNA samples.
Au-nanoprobe assay for CML diagnostics
Following calibration of the Au-nanoprobe assay, 38 myeloid
leukemia samples (16 AML sample and 22 CML samples),
previously characterized at the cell and molecular levels, were
blindly tested via the Au-nanoprobe approach and compared
to RT-nested PCR. From the attained data, we determined the
sensitivity, specificity, and positive and negative predictive
values (PPV and NPV, respectively) for the Au-nanoprobe
assay (Fig. 4; Table 1).
Fig. 2 Au-nanoprobe detection of the e14a2 BCR-ABL1 transcript
variant. a UV-vis spectra before salt addition (Probe, red); after the
addition of salt in absence of any target (blank, blue), presence of the
e14a2 (green) or e13a2 (purple) BCR-ABL1 synthetic oligonucleotides. b
Specificity of the Au-nanoprobe towards different synthetic
oligonucleotides. A threshold of 0 for Au-nanoprobe aggregation [ln
(rAbs)] was considered for discrimination between positive and
negative detection. The error bars represent the standard error of the
mean from three independent assays. *Statistically significant difference
with P value <0.001, in comparison to e13a2 condition (post hoc Tukey’s
test)
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Samples were scored negative for e14a2 based on ln(rAbs)
<0. Twelve clinical samples were correctly scored as positive
for the e14a2 transcript and the remaining scored as negative.
Even though all AML bone marrow samples were found neg-
ative for t(9;22) by FISH analysis, the Au-nanoprobe method
was sensitive enough to detect one AML sample harboring the
e14a2 fusion transcript, confirmed by RT-nested PCR.
Moreover, the Au-nanoprobe procedure allowed to scrutinize
peripheral blood follow-up samples expressing the e14a2 tran-
script. Sample 34, previously determined to express BCR-
ABL1 levels of 0.34 % (International Scale, IS), was correctly
scored as positive. According to the 2015 ELN guidelines,
these levels define a complete cytogentic response
(CCyR) [26].
Care should be taken when borderline values are obtained,
as seen in samples 28 and 38, to avoid the occurrence of false-
positives. However, results based on ln(rAbs) are in accor-
dance with RT-nested PCR results. PPV (12 true positive hits
out of 12 positive calls) and NPV (26 true negative hits out of
26 negative calls) of 100 % indicate that the Au-nanoprobe
assay under these conditions is a reliable test to scrutinize
leukemia patients expressing the e14a2 fusion transcript.
Discussion
The rapid and fast molecular characterization of CML patients
is of utmost relevance if suitable therapy is to be initiated.
Routine molecular diagnostics requires cumbersome equip-
ment and specialized technicians to evaluate the presence of
the characteristic BCR-ABL1 fusion transcripts that constitute
Fig. 3 Au-nanoprobe detection of the e14a2 BCR-ABL1 transcript
variant in total RNA samples. RNA was extracted from cell lines
(HL60, K562, and BV173). a Agarose (2 %) gel electrophoresis
showing nested-PCR products using standardized primers for the detec-
tion of the e14a2 (360 bp) and e13a2 (285 bp) transcripts. First lane is
DNA ladder (GeneRuler, Fermentas). b e14a2 Au-nanoprobe detection
assay. A threshold of 0 for Au-nanoprobe aggregation [ln (rAbs)] was
considered for discrimination between positive and negative detection.
The error bars represent the standard error of the mean from at least three
independent assays. *Statistically significant difference with P value
<0.001, in comparison to HL60 or BV173 samples (post hoc Tukey’s
test)
Fig. 4 Au-nanoprobe detection of the e14a2 BCR-ABL1 transcript
variant in total RNA clinical samples. RNA extracted from bone
marrow or peripheral blood samples from patients previously diagnosed
with AML (1–16) or CML (17–38). a Agarose (2 %) gel electrophoresis
showing nested-PCR products using standardized primers for the
detection of the e14a2 (360 bp) and e13a2 (285 bp) transcripts. Lanes L
refer to DNA ladder (GeneRuler, Fermentas): 200, 300, 400, and 500 bp
(from bottom to top). b e14a2 Au-nanoprobe assay. A threshold of 0 for
Au-nanoprobe aggregation [ln (rAbs)] was considered for discrimination
between positive and negative detection. The error bars represent the
standard error of the mean from at least three independent assays.
*Statistically significant difference with P value <0.001, in comparison
to sample 1 (post hoc Tukey’s test)
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the hallmark of this disease. Here, we demonstrated for the
first time that the Au-nanoprobe system based on the non-
cross-linking mechanism may be used to rapidly identify
e14a2-positive patients. Besides being able to detect a clinical
sample with a BCR-ABL1 fusion transcript, this approach
allowed to discriminate between the two most frequent iso-
forms of this genetic abnormality—e13a2 and e14a2—that
alone account for more than 95 % of CML cases. The attained
PPVand NPV indicate that the Au-nanoprobe assay is suitable
for the direct screening of patients’ mRNAwith obvious ad-
vantages in terms of time. It should be noted that the Au-
nanoprobe assay detects the fusion transcript directly from
RNA extracted from patient samples and, thus, is free from
the stochastic bias introduced by the standard methodologies
involving enzymatic retro-transcription into cDNA followed
by PCR. Because it avoids these reaction steps, the Au-
nanoprobe approach is much faster and simple, reducing the
detection time frame from 9 h, required for RT-nested PCR
alone, to 1 h and 30 min.
Diagnostic confirmation of myeloid leukemia patients
where the Ph chromosome is undetectable by chromosome
banding analysis or FISH is a major concern. Results achieved
with an e14a2 expressing AML sample (negative for t(9;22)
negative by cytogenetic analysis) and with follow-up samples
with BCR-ABL1 levels as low as 0.34 % (IS) indicate the Au-
nanoprobe methodology is suitable for screening patients that
exhibit a CCyR but still did not achieve a major molecular
response (MMR). Note that ELN recommends the assessment
and monitoring of the disease by RT-qPCR on buffy coat
blood cells every 3 months, not only after a CCyR has been
achieved but also from the beginning [26]. The Au-nanoprobe
methodology would be highly advantageous in these consec-
utive tests due to its simplicity and low cost.
The Au-nanoprobe assay performance suggests that it
might be useful for a combined diagnostics strategy: early
screening via the Au-nanoprobes for point-of-care to quickly
identify CML samples, followed by standard protocol on neg-
ative samples.
The possibility of fast and cheap screening technology
based on RNA samples at admission is clearly advantageous.
This is particular relevant for countries where the economic
burden of molecular diagnostics of rare diseases is way too
high to allow routine testing via proposed guidelines.
Considerable time would be saved from the time of admission
to the start of therapy, which in turn would impact on therapy
success with advantages for patients.
The overall cost of the Au-nanoprobe assay is approxi-
mately €0.20 per sample without the need of dedicated instru-
mentation. This is particularly relevant considering that the
percentage of newly reported cases of CML occurring in
low- to middle-income countries has more than tripled over
the past 40 years and that only about 5 % of the global re-
sources spent on cancer are deployed in these countries [29,
30]. CML is one of the commonest adult leukemia in Indian
population accounting for 30 to 60% of all adult leukemia, yet
little is known about the epidemiology of CML in such re-
gions mostly due to poor registries, lack of conclusive molec-
ular diagnosis, and the prohibitive cost of CML molecular
characterization [31, 32]. Indeed, the first molecular test to
measure BCR-ABL1 in sub-Saharan Africa was performed in
2011 in Ethiopia [33]. The availability of rapid and cost-
effective tests should result in reducing the rate of misclassi-
fications for leukemia and will likely improve CML incidence
and mortality rates in low- to medium-income countries.
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